Efficacy of Sumatriptan With Naprosyn in Migraine With Aura

Exclusion Criteria

• •Subjects who have a significant systemic disease other than migraine that is equally painful or more painful.
• •Subjects who have other progressive neurological disorders.
• •Subjects who have more than 8 migraines or 15 headache days per month.
• •Subjects who have previously taken Treximet and failed due to lack of efficacy or adverse side effects.
• •Subjects who carry the diagnosis of chronic tension type headache or cluster headache based on the International Headache Society criteria.
• •Subject should not have received any other investigative drug within 3 months prior to enrollment in the study.
• •Subject who have the diagnosis of seizure disorder, chronic daily headache, uncontrolled hypertension, cardiovascular disease, history of stroke, basilar or hemiplegic migraine, hepatic disease, or active peptic ulcer disease.
• •Subjects currently taking or in 3 months prior to study, use of prophylactic migraine medications.
• •Subjects who have a known allergy to Sumatriptan or Naprosyn.
• •Subjects who in the opinion of Dr. Mechtler have a condition for which they should not be enrolled in the study.